{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05768139",
            "orgStudyIdInfo": {
                "id": "STX-478-101"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-000442-41",
                    "type": "EUDRACT_NUMBER"
                },
                {
                    "id": "2023-504807-94-00",
                    "type": "OTHER",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "Scorpion Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors",
            "officialTitle": "First-in-Human Study of STX-478, a Mutant-Selective PI3K\u03b1 Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "first-in-human-study-of-stx-as-monotherapy-and-in-combination-with-other-antineoplastic-agents-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-02-28",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-02-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-01",
            "studyFirstSubmitQcDate": "2023-03-13",
            "studyFirstPostDateStruct": {
                "date": "2023-03-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Scorpion Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with advanced solid tumors with certain mutations.\n\nPart 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors and breast cancer; Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with breast cancer.\n\nEach study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "Gynecologic Cancer",
                "HNSCC",
                "Solid Tumors, Adult"
            ],
            "keywords": [
                "Breast Neoplasms",
                "Neoplasms by Site",
                "Neoplasms",
                "Breast Diseases",
                "HER2-negative breast cancer",
                "HR-positive breast cancer",
                "Gynecologic cancer",
                "Endometrial cancer",
                "Ovarian cancer",
                "Cervical cancer",
                "Head and neck cancer",
                "Head and neck squamous cell carcinoma",
                "Fulvestrant",
                "Antineoplastic Agents",
                "PI3K\u03b1",
                "PI3K alpha",
                "PI3K\u03b1 mutation",
                "Alpelisib",
                "STX-478",
                "PI3K\u03b1 inhibitor",
                "Estrogen Receptor Antagonists",
                "Estrogen Antagonists",
                "Hormone Receptor Antagonists",
                "Hormone Antagonists",
                "Hormones, Hormone Substitutes, and Hormone Antagonists",
                "Physiological Effects of Drugs"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 400,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1.1: Dose Escalation (Advanced Solid Tumors and Breast)",
                    "type": "EXPERIMENTAL",
                    "description": "* Cohort A0: Advanced Solid tumors expressing PI3K\u03b1 mutations.\n* Cohort A1: HR+/HER2- breast cancer expressing PI3K\u03b1 H1047X mutations or other kinase domain mutations.",
                    "interventionNames": [
                        "Drug: STX-478"
                    ]
                },
                {
                    "label": "Part 1.2-DE: Dose expansion at MTD",
                    "type": "EXPERIMENTAL",
                    "description": "* Cohort A2: Gynecologic cancers\n* Cohort A3: HNSCC\n* Cohort A4: Other solid tumors not included in Cohorts A0, A1, or A2\n* Mutations for Cohorts A2, A3, and A4: PI3K\u03b1 H1047X mutations or other kinase domain mutations\n* Cohort A5: Solid tumors expressing PI3K\u03b1 helical domain mutations (E542/E545)",
                    "interventionNames": [
                        "Drug: STX-478"
                    ]
                },
                {
                    "label": "Part 1.2-DS: RP2D Selection (Breast)",
                    "type": "EXPERIMENTAL",
                    "description": "Recommended Phase 2 dose (RP2D)\n\nCohort A1: HR+/HER2- breast cancer expressing PI3K\u03b1 H1047X mutations or other kinase domain mutations.",
                    "interventionNames": [
                        "Drug: STX-478"
                    ]
                },
                {
                    "label": "Part 1.3: RP2D Expansion (Breast)",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort A1: HR+/HER2- breast cancer expressing PI3K\u03b1 H1047X mutations or other kinase domain mutations.",
                    "interventionNames": [
                        "Drug: STX-478"
                    ]
                },
                {
                    "label": "Part 2.1: RP2D Selection",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort B: HR+/HER2- breast cancer expressing PI3K\u03b1 H1047X mutations or other kinase domain mutations.",
                    "interventionNames": [
                        "Drug: STX-478",
                        "Drug: Fulvestrant"
                    ]
                },
                {
                    "label": "Part 2.2: RP2D Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort B: HR+/HER2- breast cancer expressing PI3K\u03b1 H1047X mutations or other kinase domain mutations.",
                    "interventionNames": [
                        "Drug: STX-478",
                        "Drug: Fulvestrant"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "STX-478",
                    "description": "STX-478 is a second generation, mutant-selective, oral PI3K\u03b1 small molecule allosteric inhibitor.",
                    "armGroupLabels": [
                        "Part 1.1: Dose Escalation (Advanced Solid Tumors and Breast)",
                        "Part 1.2-DE: Dose expansion at MTD",
                        "Part 1.2-DS: RP2D Selection (Breast)",
                        "Part 1.3: RP2D Expansion (Breast)",
                        "Part 2.1: RP2D Selection",
                        "Part 2.2: RP2D Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fulvestrant",
                    "description": "Fulvestrant will be administered according to local labeling.",
                    "armGroupLabels": [
                        "Part 2.1: RP2D Selection",
                        "Part 2.2: RP2D Expansion"
                    ],
                    "otherNames": [
                        "Faslodex"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1.1 (Dose Escalation): Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)",
                    "timeFrame": "First 28 days of treatment"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): Proportion of participants who experience at least 1 DLT during the first 28 days of treatment.",
                    "timeFrame": "First 28 days of treatment"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): Cmax of STX-478",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): AUC(0-inf) of STX-478",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): AUC(0-t) of STX-478",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): AUC(0-\u03c4) of STX-478",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): Change from baseline in ctDNA levels.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): Changes in circulating markers of glucose metabolism as assessed by changes in circulating glycosylated hemoglobin [HbA1c]",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): Changes in circulating markers of glucose metabolism as assessed by circulating fasting plasma glucose.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): Changes in circulating markers of glucose metabolism as assessed by circulating C-peptide.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): Objective response rate (ORR).",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): Incidence of TEAEs/SAEs \u2265 grade 2.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Part 1.1 (Dose Escalation): Frequency of TEAEs according to CTCAE v5.0 criteria.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "RP2D Selection (Parts 1.2-DS and 2.1): Cmax of STX-478",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "RP2D Selection (Parts 1.2-DS and 2.1): AUC(0-inf) of STX-478",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "RP2D Selection (Parts 1.2-DS and 2.1): AUC(0-t) of STX-478",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "RP2D Selection (Parts 1.2-DS and 2.1): AUC(0-\u03c4) of STX-478",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "RP2D Selection (Parts 1.2-DS and 2.1): Change from baseline in ctDNA levels.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "RP2D Selection (Parts 1.2-DS and 2.1): Changes in circulating markers of glucose metabolism as assessed by changes in circulating glycosylated hemoglobin [HbA1c]",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "RP2D Selection (Parts 1.2-DS and 2.1): Changes in circulating markers of glucose metabolism as assessed by circulating fasting plasma glucose.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "RP2D Selection (Parts 1.2-DS and 2.1): Changes in circulating markers of glucose metabolism as assessed by circulating C-peptide",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Parts 1.2-DS and 2.1 (RP2D Selection): ORR",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Parts 1.2-DS and 2.1 (RP2D Selection): Frequency counts and percentages of AEs based on MedDRA and CTCAE v5.0",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Parts 1.2-DS and 2.1 (RP2D Selection): Proportion of participants with DLTs.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Parts 1.2-DS and 2.1 (RP2D Selection): Change in ECOG performance status.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Parts 1.2-DE, 1.3, and 2.2 (Dose Expansion): ORR defined as the percentage of participants with partial response or complete response based on RECIST 1.1.",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Has an advanced or refractory solid tumor malignancy that is metastatic or locally advanced and unresectable (as specified by Cohort)\n2. Has a new or recent tumor biopsy (collected at screening, if feasible) or archival tumor specimen within 10 years prior to screening\n3. Has a tumor that harbors a documented PI3K\u03b1 mutation (cohort specific criterion for cohort-specific mutation types) obtained either from tumor or plasma samples, determined by PCR or NGS-based assay as an FDA-approved test in US, CE marked in EU, or obtained as part of normal clinical care in a CLIA certified or similarly certified laboratory.\n4. Is \u226518 years of age at the time of signing the ICF\n5. Has an ECOG performance status score of 0 or 1 at screening\n\nKey Exclusion Criteria:\n\n1. Has history (within \u22642 years before screening) of a solid tumor or hematological malignancy that is histologically distinct from the cancers being studied\n2. Has symptomatic brain or spinal metastases\n3. Has a tumor with known mutations/deletions in PTEN and activating mutations in AKT (E17K) confirmed by a CLIA-certified or similarly certified laboratory\n4. Has an established diagnosis of diabetes mellitus type 1 or has uncontrolled diabetes mellitus type 2 (based on FPG and HbA1c thresholds defined in the inclusion criteria) requiring antihyperglycemic medication\n5. Cohorts A0, A1, A2, A3, A4, A5 and B: Has had prior treatment with PI3K/AKT/mTOR inhibitor(s), except in certain circumstances\n6. Has had treatment with any local or systemic antineoplastic therapy or investigational anticancer agent within 14 days or 4 half-lives, whichever is longer, prior to the initiation of study treatment up to a maximum washout period of 28 days\n7. Has toxicities from previous anticancer therapies that have not resolved to baseline levels or CTCAE grade \u22641, with the exception of alopecia and peripheral neuropathy\n8. Has had radiotherapy within 14 days before the initiation of study treatment",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "For questions concerning enrollment",
                    "role": "CONTACT",
                    "phone": "Please email:",
                    "email": "clinicaltrials@scorpiontx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Mark Chao, MD, PhD",
                    "affiliation": "Scorpion Therapeutics, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Angeles Clinic and Research Institute",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90025-6602",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California, San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "University of Colorado Anschutz Medical Center",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "Yale University",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06520",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114-2696",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Dana Farber Cancer Center",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Karmanos Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Saint Luke's Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Missouri",
                    "zip": "64111",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.09973,
                        "lon": -94.57857
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University Hospitals Cleveland Medical Center",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44106",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Stefanie Spielman Comprehensive Breast Cancer",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43212",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "University of Oklahoma",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104-5418",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Mary Crowley Cancer Research",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Texas Oncology - Baylor Charles A. Sammons Cancer Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75246",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "The University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Institut Bergonie City: Bordeaux",
                    "status": "RECRUITING",
                    "city": "Bordeau",
                    "zip": "33000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.32158,
                        "lon": 3.20107
                    }
                },
                {
                    "facility": "Institut Gustave Roussy",
                    "status": "RECRUITING",
                    "city": "Villejuif",
                    "zip": "94800",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "Fondazione Policlinico Universitario A Gemelli-Rome",
                    "status": "RECRUITING",
                    "city": "Roma",
                    "state": "Lazio",
                    "zip": "00168",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 41.89193,
                        "lon": 12.51133
                    }
                },
                {
                    "facility": "NEXT Oncology - Hospital Quironsalud Madrid",
                    "status": "RECRUITING",
                    "city": "Pozuelo De Alarc\u00f3n",
                    "state": "Madrid",
                    "zip": "28223",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.43293,
                        "lon": -3.81338
                    }
                },
                {
                    "facility": "START Barcelona_HM Nou Delfos",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08023",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Instituto de Investigacion Oncologica Vall d'Hebron",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Cli\u0301nico San Carlos",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "START Madrid_Hospital Universitario Fundacion Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28050",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "START Madrid_Hospital Universitario HM Sanchinarro",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28050",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5830",
                    "name": "Uterine Cervical Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077267",
                    "term": "Fulvestrant"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000065171",
                    "term": "Estrogen Receptor Antagonists"
                },
                {
                    "id": "D000004965",
                    "term": "Estrogen Antagonists"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M1723",
                    "name": "Fulvestrant",
                    "asFound": "Challenge",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M8114",
                    "name": "Estrogen Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30483",
                    "name": "Estrogen Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}